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Abstract
The use of animals lacking genes or expressing genes 
under the control of cell-specific promoters has sig-
nificantly increased our knowledge of the genetic and 
molecular basis of physiopathology, allowing testing 
of functional hypotheses and validation of biochemical 
and pharmacologic approaches in order to understand 
cell function. However, with unexpected frequency, 
gene knockout animals and, more commonly, animal 
models of transgenesis give experimental support to 
even opposite conclusions on gene function. Here we 
summarize what we learned on the role of cyclooxy-
genase 2 (COX-2) in liver and revise the results ob-
tained in 3 independent models of mice expressing a 
COX-2 transgene specifically in the hepatocyte. Upon 
challenge with pro-inflammatory stimuli, the animals 
behave very differently, some transgenic models hav-
ing a protective effect but others enhancing the injury. 
In addition, one transgene exerts differential effects on 
normal liver physiology depending on the transgenic 
animal model used. 
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INTRODUCTION
Bioactive lipids, including prostaglandins and thrombox-
anes - collectively known as prostanoids - are involved 
in many physiopathological processes ranging from 
vascular function to gastric mucosa integrity, inflamma-
tion and development/progression of  various types of  
oncologic processes including colorectal cancer[1-5]. These 
prostanoids are synthesized from arachidonic acid by the 
sequential action of  cyclooxygenase (COX) and a specific 
prostaglandin or thromboxane synthase. Two isoforms 
of  COX exist: COX-1 that is constitutively expressed in 
almost all tissues and is responsible for the homeostatic 
synthesis of  prostanoids, and COX-2 that is expressed 
upon response to cell stressors, such as pro-inflammatory 
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cytokines, growth factors and hormones[2,6-8]. Whereas 
COX-1 exhibits a modest but continuous synthesis of  
prostanoids, COX-2 is involved in the high throughput 
synthesis of  these bioactive lipids under pathological 
conditions. Mice lacking COX-1, COX-2 or both isoen-
zymes have been generated and these animals are fully 
viable despite the observation of  alterations in fertility 
(the COX-2 deficient females are sterile) and the appear-
ance of  nephropathies during aging[2,9,10]. In adult liver, 
the expression of  COX-2 under rapid response to a pro-
inflammatory challenge is almost restricted to the non-
hepatocyte cell population. However, under chronic 
pro-inflammatory conditions hepatocytes express this 
isoenzyme and the contribution of  the increased synthe-
sis of  prostanoids to liver pathology is a current subject 
of  research[11-13]. To better approach the study of  COX-2 
expression as an early cause of  liver pathology, various 
groups engineered mice that expressed this isoenzyme 
specifically in the hepatocytes. The results obtained using 
these animal models are the subject of  this review and 
highlight the need to interpret the data from animal mod-
els with a certain caution.
GENE TARGETING IN LIVER INJURY AND 
REGENERATION
The development of  targeted animal models to answer 
key biological questions in some cases requires appraisal 
to understand why animals lacking the same gene but 
generated under different genetic backgrounds or gene-
deletion strategies result in different and sometimes even 
opposite physiopathological conclusions. One case is 
liver regeneration after partial hepatectomy where only 
a reduced number of  genes appeared to be essential for 
the survival following resection of  two-thirds of  the 
liver[14-19]. Cumulative studies in this area identified about 
70 genes whose expression increased following partial 
hepatectomy; interestingly, despite the large number of  
signals controlling the early steps of  regeneration only 
a handful have been described to play a critical role in 
the successful outcome of  the process. Models in which 
liver regeneration is impaired after partial hepatectomy 
are animals deficient of  insulin-like growth factor-
1-binding protein, TAB2 (transforming growth factor-
β-activated kinase 1-binding protein 2)-a transforming 
growth factor-activated kinase-1 interacting protein 
involved in the early response to interleukin-1β (IL-1β), 
or animals overexpressing transforming growth factor-β 
(TGF-β)[20-22]. Examples of  relevant genes for regenera-
tion are those controlling commitment to proliferation 
or inhibiting apoptosis, such as c-met, pdk1, p75ntr (the 
neurotrophin receptor in stellate cells), and gadd45b[23-26]. 
Previous studies reported delayed regeneration and 
sometimes increased death in animals lacking il-6, stat-3, 
cox-2 or nos-2[2,9,27-29], but further studies notably found an 
attenuated impact of  the deficiencies in these genes in 
terms of  liver mass recovery and survival. One extreme 
example is the requirement of  caveolin-1 for regenera-
tion that in one model has been described to be “a gene 
essential for liver regeneration”[30], whereas in the com-
mercially available caveolin-1-deficient mice this gene 
appears to be absolutely “dispensable” with the peculiar-
ity of  an accelerated regeneration and, therefore, being 
a positive condition for a rapid liver mass recovery[31]. 
The reasons for these discrepancies lie with the differ-
ent genetic backgrounds of  both mice strains. Indeed, in 
those caveolin-1-deficient animals that died after partial 
hepatectomy, there was partial restoration of  the liver 
mass but they died at day 4-5 post-surgery, a situation 
that could be overcome after administration of  glucose, 
suggesting that a metabolic problem was the most likely 
defect in these animals rather than deficient cell replica-
tion and growth[30]. Indeed, in addition to the caveolin-
1-deficient mice, there are also gene-targeted animals 
that exhibit an accelerated early proliferation and liver 
mass recovery, among them animals deficient in pai-1, 
timp-1, ikk2 or socs-3[32-35]. Finally, there are a few mod-
els that, despite being unable to restore liver cellularity 
because of  deficient hepatocyte proliferation/division, 
show liver growth and fully restored hepatic function 
through an hypertrophic response with multinucleated 
and polyploid hepatocytes[36].
COX-2 TARGETING IN LIVER
As previously mentioned, prostaglandin (PGs) synthesis 
in mammals is carried out by the expression of  2 forms 
of  cyclooxygenase. COX-1 is constitutively expressed in 
most tissues and has a narrow specificity for substrates, 
preferentially using arachidonic acid and releasing PGs 
that are involved in the physiological action of  these 
lipid mediators. However, for expression of  COX-2, the 
inducible enzyme, in various tissues, a high throughput 
synthesis of  PGs occurs both from arachidonic acid 
and other polyunsaturated fatty acids. These PGs are in-
volved in the regulation of  physiopathological responses 
as diverse as inflammation, tumor development and pro-
gression, and cell growth[1,3]. 
One interesting observation in the liver is that nor-
mal adult hepatocytes, either in primary culture or in vivo, 
fail to express COX-2 upon challenge with pro-inflam-
matory stimuli, including toll-like receptor ligands and 
combinations of  tumor necrosis factor-α (TNF-α), IL-
1β and interferon-γ (IFN-γ). This lack of  inducibility by 
pro-inflammatory mediators occurs in adult hepatocytes, 
but not in hepatocytes from fetal or early newborn ani-
mals or in hepatic-derived stable cell lines[2,11,37]. Previous 
studies indicated that this behavior resulted from the 
presence of  elevated levels of  CCAT/enhancer binding 
protein-α (C/EBP-α), a transcription factor that is high-
ly expressed in the adult hepatocyte and that interferes 
with the commitment of  the cells to proliferate[9]. This 
absence of  COX-2 expression has also been observed in 
in vivo models of  sepsis, where the production of  PGs in 
the liver is accomplished by the expression of  COX-2 in 
non-hepatocyte cells, mostly Kupffer cells and infiltrat-
ing macrophages[11,13]. These observations reinforce the 
role of  liver infiltration by circulating inflammatory cells 
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in the release of  transcellular mediators, such as PGs. 
Despite lipopolysaccharide (LPS) or a pro-inflammatory 
challenge failing to induce the expression of  COX-2 in 
hepatocytes, liver regeneration after partial hepatectomy 
promotes a rapid expression of  COX-2 and synthesis 
of  PGs[11] that contribute to the regeneration onset as 
deduced by the impaired recovery observed after admin-
istration of  selective COX-2 inhibition with COX inhibi-
tors or from animals lacking the COX-2 gene[2]. Indeed, 
COX-2-deficient animals exhibited a full recovery of  
liver mass and function after partial hepatectomy with a 
delayed early commitment to proliferation[2,9,11,38]. The si-
multaneous absence of  COX-2 and other genes relevant 
for liver regeneration, such as nitric oxide synthase-2 
resulted in an impaired liver mass recovery after partial 
hepatectomy leading to animal death[39,40]. Dual deficien-
cies of  COX-2 and other genes relevant for liver func-
tion and regeneration may help to identify targets critical 
for hepatocyte survival.
COX-2 TRANSGENESIS AND LIVER 
INJURY
More intriguing are the models of  COX-2 transgen-
esis that lead to different end-responses without a clear 
reason. One example came recently when 3 groups 
engineered mice specifically expressing COX-2 in hepa-
tocytes in order to investigate the role of  this inducible 
enzyme on liver physiopathology. As previously men-
tioned, hepatocytes only express low levels of  COX-1, 
the constitutive COX enzyme that is responsible for 
PGE2 synthesis measured in primary cultures of  hepato-
cytes. However, hepatocytes fail to express COX-2 after 
onset of  inflammation as do typically inflammation-
responsive cells, such as Kupffer and stellate cells, mac-
rophages, astrocytes and microglial cells[2,9]. Interestingly, 
in the case of  hepatocytes, only under time-dependent 
progression is COX-2 expressed as a result of  the drop 
in C/EBPα levels, among other conditions[9]. Thus, ec-
topic expression of  COX-2 in hepatocytes constitutes an 
unphysiological condition ideal for evaluating the role of  
PGs in liver pathogenesis. Recently, the COX-2 gene has 
been expressed under the control of  different specific 
promoters: apolipoprotein E[38,41], transthyretin[42,43] or the 
albumin-enhancer promoter[44,45], all 3 models giving a 
high liver-specificity in the expression of  the transgene. 
On analysis, after the selection of  the founder colonies, 
it is remarkable to observe the different intrahepatic 
levels of  PGE2 reached under each model, as summa-
rized in Table 1. This is despite the observation of  a 
robust expression of  the transgene by Western blotting 
analysis in the 3 models. More tantalizing are the effects 
upon LPS/D-galactosamine (D-GalN) challenge of  the 
transgenic animals: whereas in the third model[44], the 
expression of  the COX-2 transgene notably enhanced 
the injury, in the first model[41] a clear protection in terms 
of  transaminases release and histological integrity of  the 
tissue was observed. Perhaps the genetic background of  
the animals was also playing a role in view of  the absence 
of  liver apoptosis in the wild-type animals of  the third 
model (C57BL/6) after LPS/D-GalN treatment, where-
as those of  a C57BL/6XDBA background (first model) 
exhibited a significant apoptotic response, previously de-
scribed by many authors. This apoptosis was prevented 
after the expression of  the COX-2 transgene, and was 
lost upon pharmacological inhibition of  COX-2 with se-
lective inhibitors. However, when animal models #1 and 
#3 were confronted with the Fas/FasL challenge using 
Jo2 as the stimulus, a very potent protection against liver 
injury and animal death was observed in those animals 
that carried the COX-2 transgene, through a mechanism 
that involved Src/epidermal growth factor receptor sig-
naling[38,45]. Finally, in a methionine and choline-deficient 
diet model MCD/CCl4-induced injury, COX-2 transgen-
esis failed to exhibit any significant protection on liver 
injury (animal model #2 and reference 43).
The consequences of  transgene expression over time 
also exhibited different patterns among the animal mod-
els: whereas at 12 mo mice of  the first model did not 
exhibit histopathological symptoms of  cell infiltration or 
fibrosis, the animals of  model #2 developed significant 
inflammatory cell infiltration and hepatitis through a 
mechanism that appears to involve a persistent activa-
tion of  nuclear factor-κB. As there is a continuous ac-
tivity of  COX-2 in the hepatocyte in both models, with 
elevated PGE2 synthesis, it can be concluded that other 
factors are required for the development of  infiltration 
and spontaneous hepatitis. Interestingly, COX-2 does 
not appear to mediate the development of  liver fibrosis 
since similar results were observed in wild-type, COX-2 
knockout and COX-2 transgenic mice in an experimental 
model of  induction of  liver fibrosis[43]. 
At present, there are cumulative studies supporting 
the proliferative and antiapoptotic role of  PGs in differ-
ent models of  liver failure as well as after ischemia/reper-
fusion injury[46,47]. This protective role has been observed 
even in other tissues like cardiomyocytes[48,49]. Moreover, 
it is known that PGE2 inhibits T-cell proliferation, 
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Table 1  Summary of metabolic patterns and liver responses 
in transgenic mice with a liver-specific expression of the 
COX-2  gene
Model #1[38,41] Model #2[42,43] Model #3[44,45]
PGE2 WT vs TG 45 vs 1752 30 vs 5502 22 vs 581
Challenge
   LPS/D-GalN Protection ND Sensitization
   MCD/CCl4 ND Irrelevant ND
   Jo2 (FasL) Protection ND Protection
Transaminases after challenge
   WT/TG (UI/L) 3750/625 500/500 400/1600
Infiltration3 No Yes ND
Fibrosis3 No No No
Hepatitis3 No Yes ND
HCC-induction3 ND ND ND
1pg/mg of liver; 2pg/mg of protein; 3In animals aged 12-mo. COX-2: 
Cyclooxygenase 2; ND: Not determined; PG: Prostaglandin; LPS: 
Lipopolysaccharide; D-GalN: D-galactosamine; MCD: Methionine and 
choline-deficient diet model; HCC: Hepatocellular carcinoma; WT: Wild 
type; TG: COX-2 transgenic mice.
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and exerts a suppressant effect on type-1 immune re-
sponses in macrophages, drastically inhibiting the pro-
duction of  Th1 cytokines, such as IFN-γ and TNF-α 
and upregulating IL-10[4,7]. 
In conclusion, experiments on transgenesis need to 
take into account the biological activity of  the expressed 
protein. In the case of  COX-2, the availability of  sub-
strate for this enzyme (arachidonic acid) appears to be a 
rate-limiting step in the synthesis of  PGs. Therefore, dif-
ferent levels of  protein expression might result in similar 
levels of  PG synthesis because of  substrate restrictions 
for COX-2. In addition, the time of  activation of  the ec-
topic promoter of  the transgene, usually after or during 
the perinatal transition restricts the influence of  COX-2 in 
the embryonic steps of  development, but effects on early 
postnatal development cannot be ruled out among the 
different COX-2 transgenic models considered. This is in 
addition to the contribution of  the distinct genetic back-
grounds used in these animal models. Accordingly, caution 
must be exercised in deducing conclusions in view of  the 
arbitrary insertion of  the transgene and the fact that the 
biological repercussions of  this genetic event may have 
unexpected effects in the transcriptome, in addition to the 
specific actions of  the protein encoded by the transgene. 
Scientists are innocent players in this scenario and their 
work should be well considered, although filtered by evi-
dence coming from ancillary physiopathological data.
COX-2 TRANSGENESIS AND LIVER 
CARCINOGENESIS
Despite the constitutive presence of  COX-2 in hepa-
tocytes in the mice[38,41-45], they failed to spontaneously 
develop hepatocellular tumors, and only hepatitis and 
fibrosis was observed in model #2[42,43]. This is inter-
esting because COX-2 has been frequently associated 
with the presence of  hepatocellular tumors (but in the 
“healthy” portion of  the liver) and exacerbated COX-1 
and COX-2 expression are frequently observed in hepa-
toma cell lines[13]. In addition, targeting of  the COX 
enzymes or the PG receptors (EP1-4) contribute to an-
tiproliferative effects in these cultured cells[50,51]. Tissue-
specific constitutive expression of  COX-2 has been 
reported as a positive factor for the development of  
carcinogenesis. In mice expressing the enzyme in mam-
mary glands, the continuous release of  PGE2 has been 
reported to favor angiogenesis and development per se of  
tumorigenic foci in the mammary gland[52,53]; these data 
were corroborated by pharmacological approaches based 
on COX-2 inhibition[54]. In addition to this, constitutive 
expression of  COX-2 under the control of  the keratin 
5 promoter markedly sensitized skin to carcinogens; for 
example, under these conditions the sole challenge of  
DMBA, without further requirement of  phorbol ester 
administration or other skin tumor promoters was suf-
ficient to induce epidermal hyperplasia and frequent dys-
plastic lesions in the skin of  the transgenic animals[55,56]. 
In the gastrointestinal tract, constitutive coexpression of  
COX-2 and microsomal PGE synthase (mPGES-1; the 
enzyme that is coupled to COX-2 and directs the pros-
taglandin synthesis towards PGE2) under the control 
of  the cytokeratin 19 promoter (that targets the expres-
sion of  these transgenes in the epithelial cells of  gastric 
mucosa), resulted in animals developing hyperplasia 
and tumors in the stomach glandular anatomy through 
a process in which the contribution of  infiltrating in-
flammatory cells, mainly macrophages plays a relevant 
role[57,58]. Stable expression of  COX-2 in hepatocyte-
like cells induced proliferation, with an increase in the 
proportion of  cells in S-phase[59]. Interestingly, the basal 
protein levels of  pJNK (phosphorylated c-jun-NH2-
kinase) and p53, were greater in COX-2 expressing cells 
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Figure 1  Schematic representation of the effects of transgenic expression of cyclooxygenase 2 (COX-2) in hepatocytes. The transgene protects against 
acute liver injury, but fails to alter the response to hepatocarcinogens, such as diethylnitrosamine (DEN). KC: Kupffer cell; HC: Hepatocyte; EC: Endothelial cell; HCC: 
Hepatocellular carcinoma; WT: Wild type; TG: COX-2 transgenic mice.
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and were induced treatment with diethylnitrosamine 
(DEN). However, animals of  model #1, challenged with 
DEN did not show an increased sensitivity, compared to 
the parental strain, in developing hepatic tumors during 
the following 12 mo of  treatment (preliminary results). 
A schematic representation of  these actions of  COX-2 
in hepatocytes and livers is summarized in Figure 1.
CONCLUSION
The data reported in this review suggest that COX-2 
expression provides a continuous supply of  bioactive 
lipids that protect the liver against acute injury. However, 
attention should be paid to ensure that the substrate for 
COX-2 is available, since arachidonic acid mobilization 
requires the activation of  phospholipase A2 isoenzymes, 
a process that is not usually accomplished under in vivo 
conditions. A noteworthy point is that COX-2 may use 
other unsaturated fatty acids as substrates, releasing mol-
ecules that can activate various nuclear receptors, such as 
peroxisome proliferator-activated receptors. In addition 
to this, the fact that COX-2 is not expressed in hepato-
cytes under pro-inflammatory conditions restricts PG 
synthesis to other hepatic cells, such as Kupffer cells and 
activated macrophages. However, in the course of  pro-
gression of  hepatocellular carcinomas, it cannot be ex-
cluded that there is a transient expression of  COX-2 in 
transformed cells, as observed in many cell lines derived 
from hepatocellular carcinomas that express this enzyme 
either constitutively or after pro-inflammatory induction. 
Finally, the data from the models of  COX-2 transgenesis 
in hepatocytes support the idea that by itself, COX-2 ap-
pears not to contribute to development of  tumors in the 
full life-span of  these animals.
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